StockCIK 1393434

OCULAR THERAPEUTIX, INC (OCUL): Insider Trades and Fund Holdings

In the past 12 months, OCULAR THERAPEUTIX, INC insiders reported 0 open-market purchases worth $0 and 8 sales worth $568K; 7 of the sales were reported as made under a 10b5-1 trading plan.

0Insider buys, 12 months

$0Bought by insiders, 12 months

$568KSold by insiders, 12 months

1Tracked funds holding

Recent insider trades

Open-market purchases (code P) and sales (code S) from Form 4. Grants, option exercises and gifts are not shown. Latest filing: Oct 13, 2026.

Recent OCUL insider trades
Filed	Traded	Insider	Role	Type	Shares	Price ($)	Value	Holding	Filing
Oct 13	Oct 8	Todd AndermanGeneral Counsel	General Counsel	▼ SELL10b5-1	11,984	7.29	$87K	−7.9%	Form 4 ↗
Oct 6	Oct 2	Jeffrey S. HeierChief Scientific Officer	Chief Scientific Officer	▼ SELL10b5-1	10,869	7.05	$77K	−3.4%	Form 4 ↗
Oct 6	Oct 2	Peter KaiserChief Development Officer	Chief Development Officer	▼ SELL10b5-1	9,990	7.05	$70K	−3.8%	Form 4 ↗
Sep 2	Aug 31	Donald NotmanCOO	COO	▼ SELL	1,099	10.24	$11K	−0.3%	Form 4 ↗
Aug 26	Aug 24	Pravin DugelSee Remarks	See Remarks	▼ SELL10b5-1	21,649	10.77	$233K	−0.8%	Form 4 ↗
Aug 26	Aug 24	Jeffrey S. HeierChief Scientific Officer	Chief Scientific Officer	▼ SELL10b5-1	3,296	10.78	$36K	−1.0%	Form 4 ↗
Aug 26	Aug 24	Peter KaiserChief Development Officer	Chief Development Officer	▼ SELL10b5-1	3,035	10.77	$33K	−1.1%	Form 4 ↗
Aug 26	Aug 24	Sanjay NayakChief Strategy Officer	Chief Strategy Officer	▼ SELL10b5-1	1,897	10.78	$20K	−0.6%	Form 4 ↗

Source: SEC Form 4 filings, retrieved Oct 28, 2026. How we read filings

Insiders who traded in the past year

Insider	Role	Bought	Sells	Sold	Latest
Todd Anderman	General Counsel	$0	1	$87K	Oct 13, 2026
Jeffrey S. Heier	Chief Scientific Officer	$0	2	$112K	Oct 6, 2026
Peter Kaiser	Chief Development Officer	$0	2	$103K	Oct 6, 2026
Donald Notman	COO	$0	1	$11K	Sep 2, 2026
Pravin Dugel	See Remarks	$0	1	$233K	Aug 26, 2026
Sanjay Nayak	Chief Strategy Officer	$0	1	$20K	Aug 26, 2026

Tracked funds that report OCUL

From each fund's latest 13F. Holdings are as of quarter end and are filed up to 45 days later.

Fund	Quarter	Shares	Value	% of portfolio	Change
Renaissance Technologies	Q2 2026	378,754	$3.72M	0.01%	▼ −67.0%

Source: SEC Form 13F-HR filings, retrieved Oct 28, 2026. How we read filings

Reading these numbers

Insiders sell for many reasons: taxes, diversification, a house. Purchases with their own money are rarer and are usually read as more informative. A Form 4 is due within two business days of the trade. How to read a Form 4 →